These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3342412)

  • 21. Pharmacokinetics of low-dose 1-beta-D-arabinofuranosylcytosine given by continuous intravenous infusion over twenty-one days.
    Kreis W; Chaudhri F; Chan K; Allen S; Budman DR; Schulman P; Weiselberg L; Freeman J; Deere M; Vinciguerra V
    Cancer Res; 1985 Dec; 45(12 Pt 1):6498-501. PubMed ID: 3864533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W; Nowak B; Keating MJ
    Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S; Goto N; Nakamura T; Ueda T
    Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
    Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
    Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
    Lopez JA; Beardsley GP; Krikorian JG; Mortara RW; Agarwal RP
    Cancer Res; 1983 Nov; 43(11):5190-3. PubMed ID: 6616454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
    Furner RL; Mellett LB; Herren TC
    J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
    Harris AL
    Cancer Res; 1981 Jul; 41(7):2977-9. PubMed ID: 6941850
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Bhalla K; McCrady C
    Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Relation between plasma Ara-C and intracellular Ara-CTP levels by intermediate dose and high dose Ara-C administration in the treatment of AML].
    Yoshida T; Kobayashi K; Nakamura S; Ohtake S; Itoh K; Kanno M; Hirai J; Yasushi ; Matsuda TT
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):625-30. PubMed ID: 3162669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL; Rustum YM
    Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced serum concentrations of Ara-C using suppositories containing tetrahydrouridine as a deamination inhibitor of Ara-C.
    Liversidge GG; Nishihata T; Engle KK; Higuchi T
    J Pharm Pharmacol; 1986 Mar; 38(3):223-4. PubMed ID: 2871161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic considerations in evaluating the effects of tetrahydrouridine on 5-azacytidine chemotherapy in L1210 leukemic mice.
    Kelly CJ; Gaudio L; Yesair DW; Schoenemann PT; Wodinsky I
    Cancer Treat Rep; 1978 Jul; 62(7):1025-32. PubMed ID: 80268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
    Marsh JH; Kreis W; Barile B; Akerman S; Schulman P; Allen SL; DeMarco LC; Schuster MW; Budman DR
    Cancer Chemother Pharmacol; 1993; 31(6):481-4. PubMed ID: 8453688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.